U.S. Markets close in 3 hrs 5 mins
  • S&P 500

    3,898.61
    -25.07 (-0.64%)
     
  • Dow 30

    31,167.28
    -322.79 (-1.03%)
     
  • Nasdaq

    11,415.02
    -3.14 (-0.03%)
     
  • Russell 2000

    1,779.65
    +4.80 (+0.27%)
     
  • Crude Oil

    109.81
    +0.22 (+0.20%)
     
  • Gold

    1,840.90
    +25.00 (+1.38%)
     
  • Silver

    21.83
    +0.29 (+1.35%)
     
  • EUR/USD

    1.0594
    +0.0129 (+1.2289%)
     
  • 10-Yr Bond

    2.8320
    -0.0540 (-1.87%)
     
  • Vix

    30.45
    -0.51 (-1.65%)
     
  • GBP/USD

    1.2496
    +0.0154 (+1.2446%)
     
  • USD/JPY

    127.5180
    -0.7790 (-0.6072%)
     
  • BTC-USD

    30,173.72
    +1,026.04 (+3.52%)
     
  • CMC Crypto 200

    671.64
    +19.41 (+2.98%)
     
  • FTSE 100

    7,302.74
    -135.35 (-1.82%)
     
  • Nikkei 225

    26,402.84
    -508.36 (-1.89%)
     

Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies through its MiNK Therapeutics subsidiary (formerly AgenTus Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com